These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7964688)

  • 1. Cholinergic and peptidergic systems in PSP.
    Javoy-Agid F
    J Neural Transm Suppl; 1994; 42():205-18. PubMed ID: 7964688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia.
    Chan-Palay V
    J Comp Neurol; 1988 Jul; 273(4):543-57. PubMed ID: 2463283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinergic systems in progressive supranuclear palsy.
    Warren NM; Piggott MA; Perry EK; Burn DJ
    Brain; 2005 Feb; 128(Pt 2):239-49. PubMed ID: 15649952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease.
    Jellinger K
    J Neurol Neurosurg Psychiatry; 1988 Apr; 51(4):540-3. PubMed ID: 3379428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic cortical circuits in Parkinson's disease and in progressive supranuclear palsy: a transcranial magnetic stimulation study.
    Nardone R; Florio I; Lochner P; Tezzon F
    Exp Brain Res; 2005 May; 163(1):128-31. PubMed ID: 15754175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pedunculopontine tegmentum cholinergic loss leads to a progressive decline in motor abilities and neuropathological changes resembling progressive supranuclear palsy.
    MacLaren DAA; Ljungberg TL; Griffin ME; Clark SD
    Eur J Neurosci; 2018 Dec; 48(12):3477-3497. PubMed ID: 30339310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
    Halliday GM; Macdonald V; Henderson JM
    Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The reappraisal study of the ultrastructure of Alzheimer's neurofibrillary tangles in three cases of progressive supranuclear palsy].
    Amano N; Iwabuchi K; Yokoi S; Yagishita S; Itoh Y; Saitoh A; Nagatomo H; Matsushita M
    No To Shinkei; 1989 Jan; 41(1):35-44. PubMed ID: 2655673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications.
    Henderson JM; Carpenter K; Cartwright H; Halliday GM
    Brain; 2000 Jul; 123 ( Pt 7)():1410-21. PubMed ID: 10869053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study.
    Asahina M; Suhara T; Shinotoh H; Inoue O; Suzuki K; Hattori T
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):155-63. PubMed ID: 9703164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain somatostatin concentrations do not decrease in progressive supranuclear palsy.
    Epelbaum J; Javoy-Agid F; Hirsch E; Hauw JJ; Kordon C; Krantic S; Agid Y
    J Neurol Neurosurg Psychiatry; 1987 Nov; 50(11):1526-8. PubMed ID: 2891795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRH defects in Alzheimer's and other neurologic diseases.
    de Souza EB
    Hosp Pract (Off Ed); 1988 Sep; 23(9):59-71. PubMed ID: 2901426
    [No Abstract]   [Full Text] [Related]  

  • 13. Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy.
    Warren NM; Piggott MA; Greally E; Lake M; Lees AJ; Burn DJ
    Mov Disord; 2007 Aug; 22(11):1594-600. PubMed ID: 17534953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease.
    Pillon B; Blin J; Vidailhet M; Deweer B; Sirigu A; Dubois B; Agid Y
    Neurology; 1995 Aug; 45(8):1477-83. PubMed ID: 7644044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinergic vesicular transporters in progressive supranuclear palsy.
    Suzuki M; Desmond TJ; Albin RL; Frey KA
    Neurology; 2002 Apr; 58(7):1013-8. PubMed ID: 11940684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cerebral blood flow pattern in progressive supranuclear palsy].
    Okada K; Kobayashi S; Yamashita K; Fukuda H; Suyama N
    Rinsho Shinkeigaku; 1991 Jun; 31(6):597-602. PubMed ID: 1934773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive supranuclear palsy: neuropathologic and clinical heterogeneity.
    Gearing M; Olson DA; Watts RL; Mirra SS
    Neurology; 1994 Jun; 44(6):1015-24. PubMed ID: 8208392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration.
    Kasashima S; Oda Y
    Acta Neuropathol; 2003 Feb; 105(2):117-24. PubMed ID: 12536222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy.
    Whitehouse PJ; Vale WW; Zweig RM; Singer HS; Mayeux R; Kuhar MJ; Price DL; De Souza EB
    Neurology; 1987 Jun; 37(6):905-9. PubMed ID: 3495748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive supranuclear palsy with dementia: cortical pathology.
    Bigio EH; Brown DF; White CL
    J Neuropathol Exp Neurol; 1999 Apr; 58(4):359-64. PubMed ID: 10218631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.